6,613 Shares in Abbott Laboratories (NYSE:ABT) Acquired by Wayfinding Financial LLC

Wayfinding Financial LLC acquired a new position in Abbott Laboratories (NYSE:ABT - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 6,613 shares of the healthcare product maker's stock, valued at approximately $748,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Noble Wealth Management PBC purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. NewSquare Capital LLC grew its holdings in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after buying an additional 105 shares during the last quarter. Rialto Wealth Management LLC purchased a new position in Abbott Laboratories during the fourth quarter worth $29,000. Wingate Wealth Advisors Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at $34,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at $37,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABT has been the subject of several analyst reports. Citigroup boosted their target price on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. UBS Group upped their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Stifel Nicolaus lifted their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Royal Bank of Canada reissued an "outperform" rating and set a $135.00 price target on shares of Abbott Laboratories in a research note on Tuesday, January 21st. Finally, StockNews.com downgraded Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $137.94.

Remove Ads

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $131,123.33. Following the completion of the transaction, the executive vice president now owns 74,381 shares of the company's stock, valued at $10,277,222.77. The trade was a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Eric Shroff sold 562 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $77,651.54. Following the sale, the senior vice president now directly owns 31,970 shares in the company, valued at $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 in the last ninety days. 1.10% of the stock is owned by insiders.

Abbott Laboratories Stock Down 1.4 %

ABT stock traded down $1.75 during trading on Tuesday, reaching $125.46. The stock had a trading volume of 6,726,845 shares, compared to its average volume of 5,475,835. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a fifty day moving average price of $129.04 and a 200 day moving average price of $120.12. The company has a market capitalization of $217.59 billion, a P/E ratio of 16.40, a PEG ratio of 2.52 and a beta of 0.70. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. During the same quarter in the prior year, the business posted $1.19 earnings per share. Abbott Laboratories's revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.88%. Abbott Laboratories's dividend payout ratio is presently 30.85%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.